We assessed the prevalence of post-replicative gaps in cancer cells deficient in MRNIP, an MRE11 interactor that suppresses MRE11 exonuclease activity in vitro, and which prevents MRE11-dependent degradation of nascent DNA at stalled, reversed replication forks (8). This evidence concerns the gene MRE11 and cancer.